FNCH | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

0 0%

2 Year

395.69%

Key data

Stock price

$1.82

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

N/A

52 WEEK RANGE

N/A - N/A

52 WEEK CHANGE

N/A

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

1.606 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: Mark Smith
Region: US
Website: finchtherapeutics.com
Employees: 190
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Finch Therapeutics Group, Inc. develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection. It is also developing FIN-211 and TAK-524, which are orally administered targeted consortia product candidates.

FNCH - Finch Therapeutics Group, Inc.